Business Segments · Cost of Revenue
Life Sciences: — Cost of Revenue
STERIS Life Sciences: — Cost of Revenue decreased by 1.2% to $65.60M in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ3 2024
Last reportedQ4 2025
Rolls up toTotal Cost of Revenue
How to read this metric
An increase relative to revenue suggests margin compression due to rising input costs or manufacturing inefficiencies, whereas a decrease may indicate improved production cost management.
Detailed definition
This metric captures the direct costs associated with producing and delivering the products and services within the Life...
Peer comparison
Standard cost of goods sold (COGS) metric for a specific business segment across industrial and medical device peers.
Metric ID:
ste_segment_life_sciences_cost_of_revenueHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $57.40M | $60.90M | $66.40M | $65.60M |
| QoQ Change | — | +6.1% | +9.0% | -1.2% |
| YoY Change | — | — | +15.7% | +7.7% |
Range$57.40M – $66.40M
Avg YoY Growth+11.7%
Median YoY Growth+11.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is STERIS's life sciences: — cost of revenue?
- STERIS (STE) reported life sciences: — cost of revenue of $65.60M in Q4 2025.
- What does life sciences: — cost of revenue mean?
- The direct costs incurred to produce the goods and services sold by the Life Sciences segment.